# Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

> **NCT01273090** · PHASE1 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 34 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Lymphoma
- Lymphoproliferative Disorder
- Small Intestine Cancer
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** imetelstat sodium
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01273090
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-09
- **Final completion:** 2013-10
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2014-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01273090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01273090, "Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01273090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*